POM-V Prescription Required Companion Animal

Marbocare Flavour 5 mg Tablets for Dogs and Cats

Active ingredient: Marbofloxacin

Form

Tablet

Species

Cats Dogs

Manufacturer

Emdoka bvba

VMD MA No.

34534/3004

What it's used for

Dogs  furunculosis, cellulitis).  epididymitis.  AN: 03947/2023 & 03949/2023Page 2 of 6 Cats  

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Marbofloxacin

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Marbocare Flavour 5 mg Tablets for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Dogs

furunculosis, cellulitis).

epididymitis.

AN: 03947/2023 & 03949/2023Page 2 of 6
Cats



The recommended dose rate is 2 mg/kg/day in a single daily administration (see
table below).
AN: 03947/2023 & 03949/2023Page 4 of 6
Body WeightTablets1.3 – 2.5 kg12.6 – 5.0 kg2
To ensure a correct dosage body weight should be determined as accurately as
possible.
Dogs:

Depending on the course of the disease, it may be extended up to 40 days.

the course of the disease, it may be extended up to 28 days.

the course of the disease, it may be extended up to 21 days.
Cats:

duration is 3 to 5 days.


Do not use in dogs aged less than 12 months, or less than 18 months for
exceptionally large breeds of dogs, such as Great Danes, Briard, Bernese, Bouvier
and Mastiffs, with a longer growth period.
Do not use in cats aged less than 16 weeks.
Do not use in cases of hypersensitivity to the active substance or other
(fluoro)quinolones or to any of the excipients.
Do not use in cases of confirmed or suspected resistance to fluoroquinolones (cross
resistance).

Dogs and cats:
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Vomiting
, soft stool
, modification of thirst
,
Hyperactivity
1,2
.
These signs cease spontaneously after treatment and do not necessitate
cessation of treatment.
Transient.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

A low urinary pH could have an inhibitory effect on the activity of marbofloxacin.

Special precautions for safe use in the target species:
The fluoroquinolones have been shown to induce erosion of articular cartilage in
juvenile dogs and care should be taken to dose accurately especially in young
animals. However, at the therapeutic recommended dosage, no severe side effects
are to be expected in dogs and cats.
Some fluoroquinolones at high doses may have an epileptogenic potential. Cautious
use is recommended in dogs and cats diagnosed as suffering from epilepsy.
Fluoroquinolones should be reserved for the treatment of clinical conditions which
have responded poorly, or are expected to respond poorly to other classes of
antimicrobials. Whenever possible, use of fluoroquinolones should be based on
susceptibility testing. Use of the product deviating from the instructions given in the
SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and
may decrease effectiveness of treatment with other quinolones due to the potential
for cross-resistance. Official and local antimicrobial policies should be taken into
account when the product is used.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Avoid contact of the skin and eyes with the product.
People with known hypersensitivity to (fluoro)quinolones should avoid contact with
the veterinary medicinal product. In case of accidental ingestion seek medical advice
and show the package leaflet or the label to the physician. Wash hands after use.
AN: 03947/2023 & 03949/2023Page 3 of 6
Special precautions for the protection of the environment
Not applicable.

Fluoroquinolones are known to interact with orally administered cations (Aluminium,
Calcium, Magnesium, Iron). In such cases, the bioavailability may be reduced.
When administered together with theophylline, the half-life and thus the plasma
concentration of theophylline increase. Hence, in case of concurrent administration
the dose of theophylline should be reduced.
Do not use in combination with tetracyclines, macrolides because of the potential
antagonist effect.

This veterinary medicinal product does not require any special storage conditions.>

Not applicable.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.